Level 2: School

ESMIT Spring School 2019

May 17-19, 2019
Université de Nantes, UFR Faculty of Pharmaceutical and Biological Sciences
Nantes, France

An application has been made to UEMS-EACCME for CME accreditation of this event


icon_question_pur How to travel to Nantes

Exact Address: Université de Nantes, UFR Faculty of Pharmaceutical and Biological Sciences, 9 Rue Bias, 44000 Nantes, France

Flights to Nantes. Details such as timetables, available tickets and prices can be found on following website:

Nantes Airport 

Flights to Paris followed by a train ride to Nantes. Details such as timetables, available tickets and prices can be found on following websites:

Paris Airport       Train Connections

Find hereunder a helpful homepage where you can find the best travel route from your hometown to Nantes (or any other destination):

www.rome2rio.com


icon_question_pur How to register

Each track will allow a maximum of 30 participants. Registrations will be accepted on a first come first serve basis, however, EANM members will be given relative priority.

Online Registration (closed)

If you have any questions, please contact us: esmit@eanm.org


icon_ticket_pur Registration fees

Flat rate € 250.- for 2 Tracks

Registration fee includes:

  • Electronic course programme book including all slides
  • Coffee & Lunch breaks on each School day

Registration fee does NOT include:

  • Travel to the venue
  • Accommodation

icon_payment_pur Mode of payment

Registration fees need to be paid 4 weeks prior to the event. In case the payment is not received by this deadline, the registration needs to be cancelled. Payment can be settled by

  • credit card
  • bank transfer to:
    Bank name: Die ERSTE Bank
    Banking Code: 20111
    Account number: 28120039900
    IBAN Code: AT602011128120039900
    SWIFT Code: GIBAATWW
  • Cheques will NOT be accepted.

icon_cancellation_pur Cancellation policy

Cancellations must be notified in writing to the ESMIT Office. Telephone cancellations cannot be accepted. Substitutions will be accepted and can be made at any time. Name and e-mail address of substitutes need to be sent to the EANM office 4 weeks prior to the event. In the case of cancellation 4 weeks before the course, we will refund you the fee less a € 100,- administration charge.
After this date we cannot grant any refund for cancellations. Any refund will take place after the respective course. EANM will not be held liable for cancellation fees of hotels, airlines or other means of transportation.


Multiple Myeloma Track

Bone disease, the hallmark of multiple myeloma (MM), occurs in virtually all patients during the course of the disease, frequently impairing their quality of life, and represents a major cause of morbidity and mortality. Recently, the International Myeloma Working Group (IMWG) has clarified that more than 1 focal lesion (FL) at magnetic resonance imaging (MRI) and one or more lytic bone lesions detected on computed tomography (CT), including whole body low-dose CT (WBLDCT) or positron emission tomography (PET) integrated with computed tomography (PET/CT), fulfill the criteria for bone damage requiring therapy. In addition, emerging data support the role of the newer functional imaging techniques in predicting outcomes and/or evaluating response to therapy.

Consequently, there is a need for physician involved in oncological imaging to upstage their routine practice including FDG PET/CT for the evaluation of those patients. Interpretation of PET imaging in this field can be challenging for doctors without an extensive experience. More than in other diseases, it is of utmost importance to recognize a false positive finding and not to overestimate disease extension.

Educational Objectives

Aim of this course is to clarify the contribution of different imging modalities in Multiple Myeloma, to provide helpful criteria for FDG PET/CT interpretation and to introduce PET/CT with newer tracers.

Target Audience

  • Nuclear Medicine Doctors with previous experience in PET/CT reading

Speaker

TBC


icon_suggestedreadings_pur Preparatory eTeachings (mandatory):

Online material that needs to be viewed before attending this specific track:

Details will follow soon.


 icon_suggestedreadings_pur Suggested Readings:

Online material covering topics that might be of help for a better understanding of the Level 2 Multiple Myeloma Track

Oncology: PET in Multiple Myeloma; audio- and aideo-recorded CME 4 Session – EANM’17

Papers:

  • Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). Nanni C, Versari A, Chauvie S, Bertone E, Bianchi A, Rensi M, Bellò M, Gallamini A, Patriarca F, Gay F, Gamberi B, Ghedini P, Cavo M, Fanti S, Zamagni E. Eur J Nucl Med Mol Imaging. 2018 May;45(5):712-719. doi: 10.1007/s00259-017-3909-8. Epub 2017 Dec 21;
  • Toward a GEP-based PET in myeloma. Zamagni E, Cavo M. Blood. 2017 Jul 6;130(1):2-3. doi: 10.1182/blood-2017-05-781278;
  • Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C; ESMO Guidelines Committee. Ann Oncol. 2017 Jul 1;28(suppl_4):iv52-iv61. doi: 10.1093/annonc/mdx096.
  • Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos MA, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E. Lancet Oncol. 2017 Apr;18(4):e206-e217. doi: 10.1016/S1470-2045(17)30189-4.;
  • Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, Facon T, Benboubker L, Escoffre-Barbe M, Stoppa AM, Laribi K, Hulin C, Perrot A, Marit G, Eveillard JR, Caillon F, Bodet-Milin C, Pegourie B, Dorvaux V, Chaleteix C, Anderson K, Richardson P, Munshi NC, Avet-Loiseau H, Gaultier A, Nguyen JM, Dupas B, Frampas E, Kraeber-Bodere F. J Clin Oncol. 2017 Sep 1;35(25):2911-2918. doi: 10.1200/JCO.2017.72.2975.
  • State of the art imaging of multiple myeloma: comparative review of FDG PET/CT imaging in various clinical settings. Mesguich C, Fardanesh R, Tanenbaum L, Chari A, Jagannath S, Kostakoglu L. Eur J Radiol. 2014 Dec;83(12):2203-2223. doi: 10.1016/j.ejrad.2014.09.012.;
  • Interim PET analysis in first line therapy of multiple myeloma: Prognostic value of ΔSUVmax in the FDG-avid patients of the IMAJEM study. Bailly C, Carlier T, Jamet B, Eugene T, Touzeau C, Attal M, Hulin C, Facon T, Leleu X, Perrot A, Garderet L, Macro M, Caillot D, Moreau P, Kraeber-Bodere F, Bodet-Milin C. Clin Cancer Res. 2018 Aug 1

 icon_ruuicula_pur  Curricula Multiple Myeloma Track

The School consists of 4 parallel tracks held during 3 consecutive days. Each track takes 1,5 days and all tracks start over again, which allows each participant to attend 2 tracks in a row.

download Curriculum of Multiple Myeloma Track 1

download Curriculum of Multiple Myeloma Track 2


Neurology Track
Dementia & Parkinson

This Track offers a comprehensive overview of theoretical and practical evidence-based concepts of the use of molecular imaging in neurodegenerative diseases.

After a refresher of radiopharmaceuticals, image analysis methods and morphological and functional anatomy, the role of molecular imaging in dementia and parkinsonian syndromes will be discussed. Clinical cases are the starting point to better define the usefulness, utility and accurate reading of PET and SPECT in Alzheimer’s disease, neurodegenerative dementias and parkinsonian syndromes. Specific attention is dedicated to the definition of diagnostic algorithms in these neurological disorders (taking into account the added value of both molecular and structural/conventional imaging methods and hybrid scanners). Given the emerging role of tracers able to track in vivo neuropathological hallmarks of neurodegenerative diseases (such as amyloid and tau tracers), sessions are partially dedicated to the description of neuropathology underlying Alzheimer’s disease, dementias and parkinsonian syndromes.

Finally, future developments, including the potential role of PET/MRI, will be discussed.

Target Audience

  • Nuclear medicine physicians (in training)
  • Neuroradiologists
  • Neurologists

Educational objectives

The aim of this course is to

  • refresh neuroimaging tools and neuroanatomy
  • learn more about the neuropathology underlying parkinsonian syndromes and dementias
  • understand when to use which imaging method in parkinsonian syndromes and dementias
  • learn how to acquire and interpret dopaminergic imaging (in particular dopamine transporter imaging), brain [18F]FDG PET, amyloid PET
  • hear more about future developments such as tau imaging and the use of PET/MRI

Speakers

Silvia Morbelli
Henryk Barthel


icon_suggestedreadings_pur Preparatory eTeachings (mandatory):

Online material that needs to be viewed before attending this specific track:

  • ESMIT preparatory webinar on Radiochemical and radiopharmaceutical fundamentals of PD and dementia radiotracers of clinical use (online soon)

 icon_suggestedreadings_pur Suggested Readings:

Online material covering topics that might be of help for a better understanding of the Level 2 Neuro Track:

  • Anatomy:
  • Tracers:
  • see preparatory webinar above
  • Instrumentation:
  • Clinical bases for the use of nuclear neurology:
  • Dementia:

 icon_ruuicula_pur  Curricula Neurology Track

The School consists of 4 parallel tracks held during 3 consecutive days. Each track takes 1,5 days and all tracks start over again, which allows each participant to attend 2 tracks in a row.

download Curriculum of Neurology Track 1 (will be available soon)

download Curriculum of Neurology Track 2 (will be available soon)


Oncology Track
Theranostics of Neuroendocrine tumours

Further information will be available soon.


icon_suggestedreadings_pur Preparatory eTeachings (mandatory):

Online material that needs to be viewed before attending this specific track:

Details will follow soon.


 icon_suggestedreadings_pur Suggested Readings:

Online material covering topics that might be of help for a better understanding of the Level 2 Onco Track:

Details will follow soon.


 icon_ruuicula_pur  Curricula Oncology Track

The School consists of 4 parallel tracks held during 3 consecutive days. Each track takes 1,5 days and all tracks start over again, which allows each participant to attend 2 tracks in a row.

download Curriculum of Oncology Track 1 (will be available soon)

download Curriculum of Oncology Track 2 (will be available soon)


Musculoskeletal Track

Further information will be available soon.


icon_suggestedreadings_pur Preparatory eTeachings (mandatory):

Online material that needs to be viewed before attending this specific track:

Details will follow soon.


 icon_suggestedreadings_pur Suggested Readings:

Online material covering topics that might be of help for a better understanding of the Level 2 Musculoskeletal Track:

Details will follow soon.


 icon_ruuicula_pur  Curricula Musculoskeletal Track

The School consists of 4 parallel tracks held during 3 consecutive days. Each track takes 1,5 days and all tracks start over again, which allows each participant to attend 2 tracks in a row.

download Curriculum of Musculoskeletal Track 1

download Curriculum of Musculoskeletal Track 2

Back to top
This website uses cookies. Learn more